Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cervical cancer risk in women living with HIV across four continents: A multicohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Algorithmic prediction of HIV status using nation-wide electronic registry data

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Long-Term Virological Suppression Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord
  • Niels Obel
  • Bastian Neesgaard
View graph of relations

OBJECTIVES: Evaluate long-term rates of virological failure and treatment interruption for people living with HIV (PLWHIV) with viral suppression on first-line efavirenz + tenofovir disoproxil fumarate + emtricitabine/lamivudine (EFV + TDF + FTC/3TC), and compare these according to patient characteristics.

METHODS: PLWHIV enrolled in the Collaboration of Observational HIV Epidemiological Research Europe cohort collaboration, who started first-line EFV + TDF + FTC/3TC at age at least 16 years and had viral suppression (<200 copies/ml) within 9 months were included. Rates of virological failure (≥200 copies/ml) and (complete) treatment interruption were estimated according to years since initial suppression. We used Poisson regression to examine associations of baseline characteristics with rates of virological failure or treatment interruption.

RESULTS: Among 19 527 eligible PLWHIV with median (interquartile range) follow-up 3.7 (2.0-5.6) years after initial viral suppression, the estimated rate of the combined incidence of virological failure or treatment interruption fell from 9.0/100 person-years in the first year to less than 4/100 person-years beyond 3 years from suppression; considering only those remaining on EFV + TDF + FTC/3TC, the combined rate dropped from 8.2/100 person-years in the first year to less than 3.5/100 person-years beyond 3 years. PLWHIV with injecting drug-related or heterosexual transmission were at higher risk of virological failure or treatment interruption, as were those of Black ethnicity. PLWHIV aged less than 35 years were at higher risk of virological failure and treatment interruption.

CONCLUSION: PLWHIV starting first-line EFV + TDF + FTC/3TC had low rates of virological failure and treatment interruption up to 10 years from initial suppression. Demographic characteristics can be used to identify subpopulations with higher risks of these outcomes.

Original languageEnglish
JournalAIDS (London, England)
Volume33
Issue number4
Pages (from-to)745-751
Number of pages7
ISSN0269-9370
DOIs
Publication statusPublished - 15 Mar 2019

ID: 59412314